SCHEMBL6773566

SCHEMBL6773566

CCOC(=O)C(C)C1(N)COc2ccccc2O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
KDM4E B2RXH2 7/20 0.45
MAPT P10636 7/20 0.45
APEX1 P27695 2/20 0.45
GAA P10253 7/20 0.43
RECQL P46063 4/20 0.43
TDP1 Q9NUW8 3/20 0.43
POLB P06746 2/20 0.43
HSD17B10 Q99714 4/20 0.39
ALOX15 P16050 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PIN1 Q13526 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
ALOX12 P18054 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18151325 0.69 ATM (0.41) ALDH1A1KDM4EMAPTGAARECQL
SCHEMBL10334334 0.67 ALOX15 (0.42) ALDH1A1KDM4EMAPTAPEX1GAA
SCHEMBL25854602 0.66 GAA (0.38) ALDH1A1KDM4EMAPTAPEX1GAA
SCHEMBL6040793 0.66 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTAPEX1GAA
SCHEMBL27338645 0.66 HTR1A (0.39) MAPTALOX15MEN1KMT2ABLM
SCHEMBL11815671 0.65 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTAPEX1GAA
Hydrochloric Acid SCHEMBL10545348 0.65 ALOX15 (0.40) GAAALOX15MEN1KMT2ASMN1; SMN2
SCHEMBL10334298 0.64 ALOX15 (0.41) MAPTGAAALOX15MEN1KMT2A
Ethyl Acetate SCHEMBL28088088 0.64 CYP3A4 (0.57) ALDH1A1KDM4EMAPTGAAHSD17B10
SCHEMBL10334535 0.64 ALOX15 (0.42) ALDH1A1KDM4EMAPTAPEX1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed